Half a billion people between the ages of 15 and 49 have genital herpes. Another 3.7 billion under 50 carry oral herpes. There is no cure. The standard treatment — daily valacyclovir — suppresses outbreaks but does not eliminate the virus, requires daily compliance, and still allows transmission. A drug just demonstrated 94 percent reduction in viral shedding in a clinical trial. It could replace daily dosing with a single pill once a month. And almost nobody reported it.
What ABI-5366 Actually Did
ABI-5366, developed by Assembly Biosciences, is a helicase-primase inhibitor — a fundamentally different class of antiviral from the nucleoside analogs that have dominated herpes treatment for decades. In its Phase 1b trial, a weekly 350-milligram regimen produced a 94 percent reduction in HSV-2 viral shedding. High viral load shedding — the measure most closely associated with transmission risk — dropped by 98 percent. The genital lesion rate fell by 94 percent. These are not marginal improvements over existing therapy. They represent a different order of magnitude. The drug works by blocking the virus’s ability to unzip its own DNA for replication, hitting a target that current treatments do not reach. Assembly Biosciences is developing it for once-monthly dosing, which would transform herpes management from a daily ritual into something closer to a routine health maintenance step.
Gilead Noticed. The Media Did Not.
In late 2025, Gilead Sciences — one of the largest antiviral pharmaceutical companies in the world — licensed ABI-5366. Gilead does not acquire licensing rights to drugs it considers marginal. Phase II trials are scheduled for mid-2026. The pipeline is moving. The investment is real. And the public, by and large, has no idea this is happening. Herpes affects more people globally than almost any other infectious condition. The stigma surrounding it has driven the conversation underground for decades. But silence from the media is not the same as silence from the science. The science is loud. It is saying that the era of daily valacyclovir may be ending.
Why This Matters Beyond Convenience
The shift from daily to monthly dosing is not merely about convenience, though that alone would be significant. Daily antiviral adherence is imperfect. Missed doses allow viral reactivation, shedding, and transmission. A monthly regimen with 94 percent suppression could fundamentally alter the epidemiology of HSV-2 — not by curing the virus, but by rendering it functionally dormant for the vast majority of the time. For the 491 million people living with genital herpes, many of whom navigate relationships, disclosure conversations, and daily medication routines shaped by a diagnosis that carries disproportionate social weight, this is not a minor development. It is potentially transformative.
The Road Not Taken
While ABI-5366 moves through the pharmaceutical pipeline with Gilead’s considerable resources behind it, other avenues remain unexplored. Ivermectin, for instance, has demonstrated approximately 50 percent inhibition of human herpesvirus type 2 in laboratory studies at sub-3.2 micromolar concentrations. This is not equivalent to a 94 percent reduction in a clinical trial, but it is a signal — published, measurable, and completely unfunded for further investigation. The pattern is by now familiar: compounds that cannot generate sufficient return on investment do not receive the research investment required to determine whether they work. The question is never only about efficacy. It is about who profits from the answer.
What Functional Suppression Means
No herpes cure exists. That fact has remained unchanged for decades, and ABI-5366 does not change it. What it offers is something the field has lacked: functional suppression so effective that the practical distinction between treatment and cure narrows considerably. A person taking one pill per month who experiences a 94 percent reduction in shedding and a 94 percent reduction in lesions is, for most purposes, living as though the virus were not there. This is not a cure. But for half a billion people, it may be close enough to matter — if they ever hear about it.
The Silence Is the Story
Phase II trials begin in months. The data from Phase 1b is public. Gilead has committed resources. The WHO estimates that herpes affects billions. And the media landscape, as of April 2026, treats this as a niche pharmaceutical story rather than what it plainly is: one of the most significant developments in infectious disease management in years. Perhaps the problem is that herpes lacks the dramatic arc that drives coverage. There is no outbreak, no emergency, no press conference with a podium and flags. There are only hundreds of millions of people quietly managing a condition that just received its most promising treatment option in a generation — and a press corps that, apparently, has other priorities.
